Please assess the completion status of the following clinical trial:

Trial Title: The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In order to participate in this study, a patient MUST:~  1. Be ≥ 21 and \< 90 years of age.~ 2. Provide written informed consent.~ 3. Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.~ 4. Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensin-converting enzyme inhibition, the patient must have been on a stable dose of a clinically appropriate agent for 1 month.~ 5. Be a candidate for cardiac catheterization within 5 to 10 weeks of screening as determined by doctors.~ 6. Have an ejection fraction of less than or equal to 50% by gated blood pool scan, two-dimensional echocardiogram, CT, or left ventriculogram within the prior six months and not in the setting of a recent ischemic event.~Exclusion Criteria:~* In order to participate in this study, a patient MUST NOT:~  1. Have a baseline glomerular filtration rate ≤ 35 ml/min/1.73m2.~ 2. Have a known, serious radiographic contrast allergy.~ 3. Have a Mechanical aortic valve or heart constrictive device.~ 4. Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).~ 5. Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).~ 6. Require coronary artery revascularization. Patients who require or undergo revascularization procedures should undergo these procedures a minimum of 3 months in advance of treatment in this study. In addition, patients who develop a need for revascularization following enrollment will be submitted for this therapy without delay.~ 7. Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (non-sustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or Corrected for heart rate (QTc) interval \> 550 ms on screening ECG~ 8. Automatic Implantable Cardioverter Defibrillator (AICD) firing in the past 60 days prior to enrollment.~ 9. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/µl or platelet values \< 100,000/µl without another explanation.~ 10. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal (ULN).~ 11. Have a coagulopathy = (INR \> 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \< 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment~ 12. Have known allergies to penicillin or streptomycin.~ 13. Hypersensitivity to Dimethyl Sulfoxide (DMSO).~ 14. Be an organ transplant recipient.~ 15. Have a history of organ or cell transplant rejection~ 16. Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.~ 17. Have a non-cardiac condition that limits lifespan to \< 1 year.~ 18. Have a history of drug or alcohol abuse within the past 24 months.~ 19. Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.~ 20. Be serum positive for HIV, hepatitis BsAg or viremic hepatitis C.~ 21. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.~ 22. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: 20 million Allogeneic hMSCs (Type: EXPERIMENTAL): Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10\^8 (20 million) Allo-hMSCs.
- Group 2: 100 million Allogeneic hMSCs (Type: EXPERIMENTAL): Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10\^8 (100 million) Allo-hMSCs.

Based on this trial design, predict the completion outcome and termination type (if applicable).